Trial Profile
A Phase 1 Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Mar 2023
Price :
$35
*
At a glance
- Drugs Avapritinib (Primary)
- Indications Chronic myelomonocytic leukaemia; Haematological malignancies; Leukaemia; Mast Cell Leukemia; Mastocytosis; Myeloid leukaemia; Systemic mastocytosis
- Focus Adverse reactions; Proof of concept; Registrational
- Acronyms EXPLORER
- Sponsors Blueprint Medicines
- 12 Jan 2023 Status changed from active, no longer recruiting to completed.
- 13 Dec 2022 Results assessing long-term safety and efficacy presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 11 Dec 2022 According to a Blueprint Medicines media release, data from the trial were presented at the at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.